Efficacy and Safety of Eculizumab in Enteroaggregative <i>E. coli</i> Associated Hemolytic Uremic Syndrome

Background. Hemolytic uremic syndrome (HUS) may present atypically without the full triad of classical HUS. Eculizumab has been shown to be efficacious in complement-mediated atypical HUS and some cases of Shiga-toxin (ST) associated HUS. We report the utility of eculizumab in enteroaggregative <i>E...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Ratna Acharya, William L. Clapp, Kiran Upadhyay
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2024-01-01
Sarja:	Pediatric Reports
Aiheet:	hemolytic uremic syndrome eculizumab enteroaggregative <i>E. coli</i> children
Linkit:	https://www.mdpi.com/2036-7503/16/1/3
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!